Big pharma shares shelved compounds
This article was originally published in Scrip
Seven big pharma companies have made available to academic researchers a collection of 68 "deprioritized" drug compounds through their partnership with the UK's Medical Research Council. UK-based scientists will be allowed to apply for MRC funding to use any of the compounds in studies investigating the underlying mechanics of disease.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.